Welcome to our dedicated page for Pluri SEC filings (Ticker: PLUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pluri Inc. (PLUR) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. Pluri is a Nevada-incorporated biotechnology company that reports operating from Haifa, Israel and lists its common shares on Nasdaq and the Tel Aviv Stock Exchange. Through its filings, investors can review how Pluri describes its business, governance, capital structure and material events related to its cell-based platform and collaborative ventures.
Key documents for Pluri include current reports on Form 8-K, which the company uses to announce material agreements, board and leadership changes, equity awards and private placements. For example, recent 8-K filings describe a Securities Purchase Agreement with an entity beneficially owned by a director for a private placement of common shares and warrants, equity grants to executives and directors, and changes in board composition and committee membership following shareholder meetings. These filings also document matters such as Nasdaq listing rule compliance and shareholder voting results.
Investors analyzing PLUR can use annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) to understand the company’s description of its 3D cell expansion platform, its operations in regenerative medicine, foodtech, agtech, aesthetics and CDMO services, and its network of subsidiaries and collaborations. Proxy statements and related materials provide additional detail on board structure, compensation plans and shareholder proposals.
On Stock Titan, Pluri’s SEC filings are complemented by AI-powered summaries designed to highlight the main points of lengthy documents, such as complex agreements or governance disclosures. Users can quickly see what each filing covers, from private placement terms and warrant structures to board appointments and committee roles, and then drill down into the full text for deeper analysis. The filings page also helps track equity issuances, compensation-related grants and other regulatory information that may be relevant to understanding PLUR as a publicly traded biotechnology company.
Pluri Inc. reported wider losses and growing liquidity pressure for the six months ended December 31, 2025. Revenue was broadly flat at
Net loss rose to
The balance sheet is constrained by an EIB loan with principal of
Pluri Inc. reported that it received a notice from Nasdaq on January 20, 2026 stating that the company no longer meets Nasdaq’s continued listing standards for The Nasdaq Capital Market. Pluri’s market value of listed securities has fallen below the required
The company’s common shares will continue to trade on Nasdaq under the symbol PLUR during an initial 180‑day compliance period ending on
Pluri Inc. entered into a securities purchase agreement with Chutzpah Holdings LP, a fund beneficially owned by director Alexandre Weinstein, for a private placement of 625,000 common shares and warrants to purchase up to 625,000 additional shares. The units are priced at $4.00 per share plus warrant, for expected gross proceeds of approximately $2.5 million, with warrants exercisable immediately at $4.25 per share until June 30, 2026 and subject to a 35% beneficial ownership cap. The closing is expected on or about December 15, 2025, subject to customary conditions, and proceeds are earmarked for working capital and general corporate purposes.
The board granted 10,248 restricted stock units to the CEO and CFO and 2,885 RSUs to directors in lieu of cash compensation, vesting monthly over three months to support cost management and align incentives. Effective December 4, 2025, Alexandre Weinstein was appointed Chairman of the Board and Zami Aberman was appointed Vice Chairman, with Aberman’s consultancy agreement ending January 4, 2026.
Pluri Inc. reported that Chief Executive Officer and director Yaky Yanay received a grant of 6,588 restricted stock units of common stock on December 4, 2025, at a price of $0 per share under the company's 2019 Equity Compensation Plan.
The RSUs vest in equal installments on a monthly basis over three months following the grant date. After this award, Yanay beneficially owns 497,758 shares of common stock directly and 836 shares indirectly through Yaacov Yanay Management Ltd.
Pluri Inc. director Rami Avraham Levi reported a stock-based compensation grant on Form 4. On December 4, 2025, he acquired 653 shares of Pluri common stock as restricted stock units at a stated price of $0 per share under the company’s 2019 Equity Compensation Plan. Following this grant, he beneficially owned 18,967 shares of common stock in total. The RSUs were approved by the Board of Directors and are scheduled to vest in equal monthly installments over three months after the grant date, providing short-term, time-based equity incentives linked to continued service.
Pluri Inc. (PLUR) reported insider activity involving director and 10% owner Alexandre Weinstein and his entities Chutzpah Holdings Limited and Plantae Bioscience Ltd. On February 25, 2025, 10,250 common shares were acquired at a price of $0, held directly. On October 29, 2025, 1,002,169 pre-funded warrants with an exercise price of $0.0001 per share were exercised into common stock, resulting in 1,933,415 common shares indirectly held through Chutzpah.
Separately, on April 28, 2025, 452,702 common shares were purchased at $4.61 per share and are indirectly held through Plantae. The filing explains that Chutzpah and Plantae are controlled by Mr. Weinstein, who may be deemed to beneficially own their holdings, while formally disclaiming beneficial ownership beyond his pecuniary interest. It also notes that 84,599 common warrants related to a January 23, 2025 securities purchase agreement are exercisable until June 30, 2028.
Pluri Inc. (PLUR) reported a director’s equity award on a Form 4. On November 12, 2025, the director acquired 11,685 shares of common stock at $0, reflecting a grant of restricted stock units (RSUs) under the company’s 2019 Equity Compensation Plan. Following the transaction, the director beneficially owned 11,685 shares. The RSUs vest over three years: 50% vests ratably on a quarterly basis in the first year, then 25% in the second year and 25% in the third year.
Pluri Inc. reported that its Board granted CEO Yaky Yanay equity awards recognizing 2025 performance. The package includes 39,050 fully vested RSUs and stock options for 39,050 shares, exercisable for three years at an exercise price of $5.00 per share. The Board also approved a contingent award of 9,266 RSUs and options for 9,266 shares, with a grant date upon satisfaction of specified objectives by December 31, 2025, and the options exercisable for three years at $5.00.
Pluri Inc. (PLUR) CEO Yaky Yanay filed a Form 4 reporting equity awards on 10/15/2025. He acquired 39,050 restricted stock units at $0, which are fully vested, and 39,050 stock options with a $5 exercise price that are fully vested and expire on 10/15/2028.
Following these transactions, he beneficially owns 491,170 shares directly, plus 836 shares held indirectly through Yaacov Yanay Management Ltd. The filing lists his roles as Chief Executive Officer and Director and indicates it was filed by one reporting person.
Eitan Ajchenbaum, identified as a Director of Pluri Inc. (ticker PLUR), filed an initial Form 3 relating to an event on 09/10/2025. The filing states no securities are beneficially owned by the reporting person. The form was signed on 09/22/2025 and was filed by one reporting person.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
